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Introduction
Malignant glioma, the most common primary brain cancer, 
is divisible into histologic subgroups based on the specific types 
of glial cells involved. Despite recent advances in therapy, the 
prognosis for the majority of glioma patients remains grim. 
The most aggressive form of the disease glioblastoma multiforme 
is commonly lethal, with afflicted patients typically dying 
approximately 2 y, or less, following diagnosis. Therefore, there 
is an urgent need of novel routes of investigation in glioma 
research that might lead to more efficacious therapies to treat 
this malignancy.
Like other complex diseases, glioma is thought to result 
from both genetic and environmental factors. Several genes, 
including some belonging to the immune system, have been 
implicated in glioma pathogenesis.1-10 But the putative role of 
γ marker (GM) allotypes, encoded by three highly polymorphic 
IGHG loci11 on chromosome 14, has not been evaluated. There 
is a strong immunogenetic rationale for investigating the role 
of GM allotypes in the etiopathogenesis of glioma considering 
that these determinants modulate an immunoevasion strategy 
of human cytomegalovirus (HCMV), a common herpes 
virus that is thought to be an active promoter or oncological 
modulator of gliomagenesis.12-16 In a previous study, we showed 
that an HCMV-encoded Fcγ receptor (FcγR), employed by 
the virus to evade the effector consequences of anti-HCMV 
antibody binding, has differential affinity for IgG1 proteins 
expressing distinct GM alleles. Specifically, the HCMV FcγR 
encoded by the viral TRL11/IRL11 gene has significantly higher 
affinity for IgG1 proteins expressing the GM 3+,1-,2- allotypes 
than for those expressing the allelic GM 17+,1+,2+ allotypes.17 
These observations led us to hypothesize that these GM alleles 
might represent risk or protective factors, respectively, for the 
development of HCMV-induced glioma.18 In the present work, 
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Both genetic and environmental factors are thought to be causal in gliomagenesis. several genes have been implicated 
in glioma development, but the putative role of a major immunity-related gene complex member, immunoglobulin 
heavy chain γ (IGHG) has not been evaluated. Prior observations that IGHG-encoded g marker (gM) allotypes exhibit 
differential sensitivity to an immunoevasion strategy of cytomegalovirus, a pathogen implicated as a promoter of 
gliomagenesis, has lead us to hypothesize that these determinants are risk factors for glioma. To test this hypothesis, 
we genotyped the IGHG locus comprising the gM alleles, specifically gM alleles 3 and 17, of 120 glioma patients and 
133 controls via TaqMan® genotyping assay. To assess the associations between gM genotypes and the risk of glioma, 
we applied an unconditional multivariate logistic regression analysis adjusted for potential confounding variables. in 
comparison to subjects who were homozygous for the gM 17 allele, the gM 3 homozygotes were over twice as likely, 
and the gM 3/17 heterozygotes were over three times as likely, to develop glioma. similar results were achieved when 
analyzed by combining the data corresponding to alleles gM 3 and gM 3/17 in a dominant model. The gM 3/17 genotype 
and the combination of gM 3 and gM 3/17 were found to be further associated with over 3 times increased risk for high-
grade astrocytoma (grades iii-iV). allele frequency analyses also showed an increased risk for gliomas and high-grade 
astrocytoma in association with gM 3. Our findings support the premise that the gM 3 allele may present risk for the 
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we applied a case-control design to test the hypothesis that 
subjects expressing the GM 3 allele would be at higher risk of 
developing glioma.
Results
The demographics of our study population, including patient 
clinicopathologic features, are described in Table 1. Results of 
multivariate regression analysis to assess associations between 
GM genotypes or allele frequencies and glioma risk among 
the various histologic subgroups are presented in Table 2. 
In comparison to subjects who were homozygous for the GM 
17 allele, the GM 3 homozygotes were over twice as likely 
(OR = 2.82, CI 1.05–7.59), and the GM 3/17 heterozygotes were 
over three times as likely (OR = 3.13, CI 1.15–8.52), to develop 
glioma, irrespective of disease subtype (all grades). Similarly, in 
comparison to GM 17/17 homozygotes, GM 3/17 heterozygotes 
were over three times as likely to develop high-grade astrocytoma 
(OR = 3.37, CI 1.05–10.87). Likewise, when comparing the 
combined GM 3/3+3/17 (i.e. GM 3-carriers) genotypes to the 
GM 17/17 genotypes, the presence of the GM 3 allele conferred a 
significantly increased risk for glioma (OR = 2.95, CI 1.13–7.73) 
and high-grade astrocytoma (OR = 3.11, CI 1.01–9.62). Similar 
results were obtained when assessing the allele frequencies. 
It was shown that the GM 3 allele was a risk factor for glioma 
(OR = 1.52, CI 1.10–2.11) and high-grade astrocytoma 
(OR = 1.49, CI 1.03–2.15), when compared with the reference 
GM 17 variant. No significant associations were found between 
GM genotypes or GM alleles and the risk of oligodendroglioma.
We also applied a multivariate Cox proportional hazard model 
(adjusted for patient age and sex) to investigate the association 
between GM polymorphism and overall survival. Glioblastoma 
patients for which follow up information was available who 
carried the GM 17/17 genotype (n = 4, 2 deaths) had a longer 
median overall survival than patients carrying the GM 3/17 
(n = 18, 14 deaths) or GM 3/3 (n = 23, 17 deaths) genotypes with 
a median survival of 35 mo (range, 2–38) versus 16 mo (range, 
3–52), respectively. However, the difference was not statistically 
significant (HR = 2.78; 95% CI, 0.61–12.65, P = 0.19), probably 
due to limited sample size in analysis (Fig. 1). (The survival curves 
for the three genotypes separately are presented in Figure S1.)
Table 1. clinicopathologic features of gliomas and controls
Groups (WHO grade) N Age years (mean ± SD) Male/female ratio
controls 133 36–85 (54.80± 9.39) 1.6
glioma (all grades) 120 20–83 (56.38 ± 12.55) 1.6
astrocytoma (all grades) 97 22–83 (57.55 ± 12.21) 1.9
Oligodendroglioma (all grades) 23 20–78 (51.48 ± 13.08) 0.8
astrocytoma (grades ii-iV) 95 22–83 (57.67 ± 12.04) 1.9
astrocytoma (grades iii-iV) 90 22–83 (58.21 ± 11.80) 2.0
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significance of associations between gM genotypes or alleles and risk of glioma in various histologic subgroups. *reference genotype gM 17/17; 

























Results presented here show that carriers of the GM 3 allele 
of IgG1 have 3-fold higher risk of high-grade glioma than non-
carriers. Potential underlying mechanisms could involve a direct 
contribution of GM alleles to immunity to self and non-self 
antigens relevant to gliomagenesis. Alternatively, it is possible 
that there may be another locus affecting glioma susceptibility 
that is distinct from GM on chromosome 14 and whose alleles 
are in significant linkage disequilibrium with those of the GM 
loci. This putative linkage disequilibrium could give rise to 
the associations observed. The most relevant among the self-
antigens, immunity to which is influenced by GM alleles, are 
human epidermal growth factor receptor 1 (HER1/EGFR) and 
HER2. These tumor-associated antigens are aberrantly expressed 
in gliomas19,20 and we have previously shown that GM alleles 
epistatically interact with FcγRIIIa alleles expressed on natural 
killer cells and mediate antibody-dependent cellular cytotoxicity 
of EGFR- and HER2-overexpressing cancer cells.21 Though 
not yet investigated in glioma, antibody responses to HER2 are 
significantly associated with GM alleles in patients with breast 
cancer.22,23 This may hold for patients with glioma as well.
The most relevant among the non-self factors, immunity to 
which is influenced by GM alleles, is HCMV. As mentioned 
before, the current consensus in the glioma field is that HCMV is 
an active promoter or oncogenic modulator of gliomagenesis, not 
merely a bystander.16 GM alleles could influence HCMV-glioma 
association by influencing antibody responsiveness to viral 
epitopes and further by modulating the viral immunoevasion 
strategies. In the inflammatory autoimmune disease scleroderma 
(systemic sclerosis), HCMV appears to accelerate the development 
of disparate disease pathologies24-26 and, of particular importance, 
we have found a highly significant association between anti-
HCMV IgG antibody responses and the GM 3 and GM 17 
alleles expressed on IgG1 in these patients.27 Similar studies 
evaluating correlations between the presence of particular GM 
allelic variants and HCMV antibodies should be conducted for 
glioma patients.
GM allotypes are expressed in the constant region of γ chains. 
How could these constant-region determinants influence 
immune responsiveness thought to be exclusively associated with 
the variable-region genes? Recent investigations have challenged 
this central tenet of immunology. Several studies have shown that 
structural variation in the constant region affects the expression 
of certain idiotypes and causes variation in the specificity of 
variable-region-identical immunoglobulin molecules.28 It is 
especially noteworthy that amino acid sequence polymorphism 
in the CH1 domain of the γ1 chain—where the allelic 
determinants GM 3 and GM 17 are located—has been shown 
to modulate the kinetic competence of antigen binding sites.29 
Thus, amino acid substitutions associated with GM allotypes 
cause structural changes in the constant region, which could 
translate to structural constraints (conformation) imposed on 
the variable region, resulting in variation in antibody specificity 
and affinity.
As mentioned above, GM alleles modulate one of HCMV’s 
immunoevasion strategies. The HCMV TRL11/IRL11-
encoded FcγR—which enables the virus to evade the effector 
consequences of antibody binding, such as antibody-dependent 
cellular cytotoxicity, complement-dependent neutralization, and 
phagocytosis—discriminates between IgG1 proteins expressing 
GM 3 and GM 17 alleles. The HCMV-encoded FcγR has 
significantly higher affinity for IgG1 proteins expressing the 
GM 3+,1-,2- allotypes than for those expressing the allelic 
GM 17+,1+,2+ allotypes.17 It naturally follows that individuals 
expressing the relatively higher affinity GM 3+,1-,2- alleles 
would be more likely to have their Fc domains scavenged, thereby 
reducing their immunological competence to eliminate the virus 
through Fc-mediated effector mechanisms. Therefore, one would 
anticipate that decreased immunity against HCMV would be 
conducive to glioma development, such that the frequency of 
GM 3+,1-,2- alleles would be expected to be higher in glioma 
patients than in healthy controls. In fact, our findings are fully 
consistent with this prediction.
If GM genes are risk factors for glioma, as shown here, why have 
they not been detected by the genome-wide association studies 
(GWAS) of this malignancy?30 A likely reason underlying this 
deficiency may be the absence of these genes in many commonly 
used genotyping platforms. The IGHG gene segments harboring 
GM alleles are highly homologous (> 95%) and apparently not 
amenable to the high throughput genotyping technology used 
Figure 1. correlation analysis of overall survival of glioblastoma patients 
with gM allotypes. Multivariate cox proportional hazard model regres-
sion with respect to γ marker (gM) genotypes in the sub-groups of gM 
17/17 (n = 4) and gM 3/3 + gM 3/17 (n = 38) and glioblastoma patient 
























e28609-4 Oncoimmunology Volume 3 
in GWAS. Furthermore, because these genes were not typed in 
either the HapMap or 1000 Genomes projects, they cannot be 
imputed or tagged via linkage disequilibrium by single nucleotide 
polymorphisms (SNPs) included in the genotyping platforms. 
This underscores the necessity for the candidate gene approach 
to prospectively investigate the causal role for the IGHG gene 
complex, particularly the GM alleles, in the immunopathology 
of glioma.
Future studies involving GM allotypes and disease risk may 
also shed light on the reasons behind the racial differences in the 
prevalence of glioma. Age-adjusted glioma rates are considerably 
higher in Caucasians than in people of African descent.2 In these 
regards, it is potentially highly relevant that the GM 3 allele, 
implicated in the risk of glioma in our study here, is either absent, 
or extremely rare, in people with unmixed African ancestry.11
Future studies should also consider examining the interactive 
effects of particular candidate genes in gliomagenesis. Genes 
do not act in isolation and there is preponderant evidence that 
epistasis—modification of the action of one gene by the action 
of one, or more, other genes—plays a significant role in human 
disease processes.31-33 With this in mind, IGHG (GM allotypes) 
and HLA are excellent candidate genes for epistatic investigations 
in glioma, as both are targets of HCMV immunoevasion 
strategies17,34 and have been shown to contribute to glioma risk, 
GM alleles in the present investigation and HLA alleles in 
previous studies.1,2
To our knowledge, this is the first report implicating GM 
genes in susceptibility to glioma, a devastating and often lethal 
malignancy. Replication, using a larger, independent cohort, is 
needed to validate the results presented here.
Material and Methods
Glioma patients and controls
The study population has been described in detail elsewhere.6 
All samples with available DNA isolated from peripheral blood 
lymphocytes were included in this work. Briefly, 120 glioma 
patients were recruited at Hospital de Braga, Braga and Hospital 
S. João, Porto, Portugal. Controls consisted of 133 cancer-
free random blood donors. Both patients and controls were 
Caucasians. The study protocol was approved by the Institutional 
Ethical Committees. Peripheral blood samples from patients and 
normal controls were collected after informed consent, according 
to the Helsinki Declaration.
Quantitative PCR-based GM genotyping
At position 214 of the g1 chain, an arginine residue 
characterizes the GM 3 allele and a lysine characterizes the GM 
17 allele. This corresponds to a G to A nucleotide substitution 
in the g1 gene. We used a pre-designed TaqMan® genotyping 
assay targeting these variants from Applied Biosystems Inc., 
according to manufacturer’s instructions and employing 
the following primers and probes: forward primer (5` 
CCCAGACCTA CATCTGCAAC GTGA-3`); reverse primer 
(5` CTGCCCTGGA CTGGGACTGC AT-3`); reporter 1 
(GM 17-specific) (VIC-CTCTCACCAA CTTTCTTGT-
NFQ); reporter 2 (GM 3-specific) (FAM-CTCTCACCAA 
CTCTCTTGT-NFQ)
Statistical analyses to evaluate associations between glioma 
and GM genotype
Genotype frequencies were in Hardy–Weinberg equilibrium 
in both groups. To evaluate the effect of an IgG1 GM variant 
on the risk of glioma, odds ratios (OR) and 95% confidence 
intervals (95% CI) were estimated by unconditional multivariate 
logistic regression analysis adjusted for potential confounding 
variables (i.e., patient age and sex). We estimated ORs of 
glioma risk associated with the GM 3/3 or GM 3/17 genotype 
relative to that of GM 17/17 used as reference. We also analyzed 
a model in which the combined GM 3/3+3/17 was compared 
with the genotype GM 17/17 (reference). Additionally, the 
allelic frequency of 3 and 17 alleles was estimated, as well as the 
ORs associated with risk of glioma. Associations between GM 
variants and patient survival were assessed using a multivariate 
Cox regression model adjusted for patient age, and sex. In this 
analysis, the genotypes and patient survival for GM 3/17+GM 
3/3 were compared with those of GM 17/17 patients, again 
used as a reference standard. Our rationale for choosing the less 
frequent (GM 17) allele as reference is that our hypothesis is 
based on the fact that people expressing the GM 3 variant have 
a reduced immunological competence to eliminate HCMV and, 
as such, have an increased risk to develop glioma. Patients were 
followed until death or loss to follow-up. Statistical significance 
was defined as P < 0.05. All reported P values are 2-sided. Data 
analysis was performed using SPSS 20.0 software (SPSS, Inc.).
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